reduced risk of relapse of HPV-related oropharyngeal squamous cell carcinoma research hub

Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a therapeutic HPV DC targeting vaccine in patients with Human papillomavirus (HPV)-positive oropharyngeal cancer (HPV.DCVax)

This study is testing a new vaccine for people with throat cancer caused by HPV. It aims to see if the vaccine is safe and helps the body's immune system fight the cancer, potentially lowering the chance of the cancer coming back.